Appoints Richard Miao, Deputy Chief Financial Officer of Sema4, as interim Chief Financial Officer
Reiterates financial guidance provided on May 12, 2022
STAMFORD, Conn., June 14, 2022 (GLOBE NEWSWIRE) — Sema4 (Nasdaq: SMFR), an AI-driven genomics and clinical data intelligence platform company, today announced that its Chief Financial Officer (CFO) , Isaac Ro, will leave the company on August 9, 2022. Effective immediately, Richard Miao, Deputy CFO of Sema4, will serve as interim CFO while the company searches for a permanent CFO. Mr. Ro will provide consulting services to Sema4 for six months to facilitate a smooth transition of responsibilities.
“We are extremely grateful for Isaac’s leadership and experience who helped guide Sema4’s evolution into a publicly traded company, build a strong financial team and close the acquisition of GeneDx,” said Katherine Stueland, CEO of Sema4. “We offer Isaac our deepest gratitude and wish him much success in his next endeavour.
Ms. Stueland continued, “As we contemplate our next phase of commercial growth and continue on the path to profitability, we remain committed to further accelerating precision medicine as the standard of care. We look forward to welcoming a new Chief Financial Officer who will help us pursue our goals and our mission. »
“Sema4 has grown rapidly over the past eighteen months and has become an industry-leading health intelligence company,” said Mr. Ro. “Looking ahead, there are significant growth opportunities in many therapeutic areas as well as a path to profitability for Sema4. I am honored to have helped lead the company’s transformation and am excited about the company’s prospects. »
Mr. Miao has over 18 years of corporate finance experience across multiple growth industries and will report directly to Ms. Stueland in her interim role.
Mr. Ro’s departure is not related to a disagreement with the company’s accounting principles or practices or financial statement disclosure. The company has hired Russell Reynolds to conduct the search for Mr. Ro’s permanent replacement.
Sema4 is a patient-centric health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 transforms healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and define optimal, individualized health trajectories. Centrellis™, our innovative health intelligence platform, enables us to generate a more comprehensive understanding of disease and well-being and provide science-based solutions to the most pressing medical needs. Sema4 believes that patients should be treated as partners and data should be shared for the benefit of all.
For more information, please visit sema4.com and connect with Sema4 on Twitter, LinkedIn, Facebook and Youtube.
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our future performance and market opportunities, including our full-year 2022 financial guidance, our expectations regarding our growth and our future investments in our business, and our expectations regarding the anticipated benefits and synergies of the recent acquisition of GeneDx. These forward-looking statements are generally identified by the words “believe”, “project”, “expect”, “anticipate”, “estimate”, “intend”, “strategy”, “future”, “opportunity “, “plan,” “may,” “should,” “will,” “would,” “will,” “will,” “will likely,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, therefore, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements contained in this press release, including, but not limited to: (i) the ability to implement business plans, objectives and forecasts, and to identify and realize additional opportunities, (ii) the risk of a downturn and the changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and (iv) the risk that the anticipated benefits of the acquisition of GeneDx may not be fully realized, if at all. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission. of the United States (the “SEC”) on March 14, 2022 and other documents that we file from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to place undue reliance on any forward-looking statements, and we undertake no obligation and do not intend to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. We do not guarantee that we will meet our expectations.
Contact with Investor Relations: